Claire Clibborn
Tadworth, ENG, United Kingdom
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 11 publications
Onset and depth of response with abrocitinib versus dupilumab in adults with moderate-to-severe atopic dermatitis, including prominent head-and-neck dermatitis: A post hoc analysis of the head-to-head phase 3 JADE DARE study.
Journal: Journal of the American Academy of Dermatology
Published: April 08, 2025
Switching from Dupilumab to Abrocitinib in Patients With Moderate-to-Severe Atopic Dermatitis: A Post Hoc Analysis of Efficacy After Treatment With Dupilumab in JADE DARE.
Journal: Dermatology and therapy
Published: August 01, 2024
A Report and Proposals for Future Activity from the Inaugural Artificial Intelligence in Dermatology Symposium Held at the International Societies for Investigative Dermatology 2023 Meeting.
Journal: JID innovations : skin science from molecules to population health
Published: January 29, 2024
Abrocitinib efficacy and safety in patients with moderate-to-severe atopic dermatitis: Results from phase 3 studies, including the long-term extension JADE EXTEND study.
Journal: Journal of the European Academy of Dermatology and Venereology : JEADV
Published: February 10, 2023
Abrocitinib effect on patient-reported outcomes in patients with moderate-to-severe atopic dermatitis: Results from phase 3 studies, including the long-term extension JADE EXTEND study.
Journal: Journal of the European Academy of Dermatology and Venereology : JEADV
Published: February 10, 2023
Efficacy and safety of abrocitinib versus dupilumab in adults with moderate-to-severe atopic dermatitis: a randomised, double-blind, multicentre phase 3 trial.
Journal: Lancet (London, England)
Published: April 01, 2022
Rapidity of Improvement in Signs/Symptoms of Moderate-to-Severe Atopic Dermatitis by Body Region with Abrocitinib in the Phase 3 JADE COMPARE Study.
Journal: Dermatology and therapy
Published: November 17, 2021
Magnitude and Time Course of Response to Abrocitinib for Moderate-to-Severe Atopic Dermatitis.
Journal: The journal of allergy and clinical immunology. In practice
Published: October 27, 2021
Comparative efficacy and safety of systemic therapies used in moderate-to-severe atopic dermatitis: a systematic literature review and network meta-analysis.
Journal: Journal of the European Academy of Dermatology and Venereology : JEADV
Published: December 22, 2020
Showing 1-11 of 11
Last Updated: 09/26/2026